Suppr超能文献

百里醌通过消除CXCR4信号轴抑制乳腺癌细胞的骨转移。

Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis.

作者信息

Shanmugam Muthu K, Ahn Kwang Seok, Hsu Annie, Woo Chern Chiuh, Yuan Yi, Tan Kwong Huat Benny, Chinnathambi Arunachalam, Alahmadi Tahani Awad, Alharbi Sulaiman Ali, Koh Angele Pei Fern, Arfuso Frank, Huang Ruby Yun-Ju, Lim Lina H K, Sethi Gautam, Kumar Alan Prem

机构信息

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

College of Korean Medicine, Kyung Hee University, Seoul, South Korea.

出版信息

Front Pharmacol. 2018 Dec 4;9:1294. doi: 10.3389/fphar.2018.01294. eCollection 2018.

Abstract

Overexpression of chemokine receptor type 4 (CXCR4) has been found to be associated with increased cell proliferation, metastasis and also act as an indicator of poor prognosis in patients with breast cancer. Therefore, new agents that can abrogate CXCR4 expression have potential against breast cancer metastasis. In this study, we examined the potential effect of thymoquinone (TQ), derived from the seeds of , on the expression and regulation of CXCR4 in breast cancer cells. TQ was found to inhibit the expression of CXCR4 in MDA-MB-231 triple negative breast cancer (TNBC) cells in a dose- and time-dependent manner. It was noted that suppression of CXCR4 by TQ was possibly transcriptionally regulated, as treatment with this drug caused down-regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and suppression of NF-κB binding to the CXCR4 promoter. Pretreatment with a proteasome inhibitor and/or lysosomal stabilization did not affect TQ induced suppression of CXCR4. Down-regulation of CXCR4 was further correlated with the inhibition of CXCL12-mediated migration and invasion of MDA-MB-231 cells. Interestingly, it was observed that the deletion of p65 could reverse the observed anti-invasive/anti-migratory effects of TQ in breast cancer cells. TQ also dose-dependently inhibited MDA-MB-231 tumor growth and tumor vascularity in a chick chorioallantoic membrane assay model. We also observed TQ (2 and 4 mg/kg) treatment significantly suppressed multiple lung, brain, and bone metastases in a dose-dependent manner in a metastasis breast cancer mouse model. Interestingly, H&E and immunohistochemical analysis of bone isolated from TQ treated mice indicated a reduction in number of osteolytic lesions and the expression of metastatic biomarkers. In conclusion, the results indicate that TQ primarily exerts its anti-metastatic effects by down-regulation of NF-κB regulated CXCR4 expression and thus has potential for the treatment of breast cancer.

摘要

趋化因子受体4(CXCR4)的过表达已被发现与细胞增殖增加、转移有关,并且是乳腺癌患者预后不良的一个指标。因此,能够消除CXCR4表达的新型药物具有对抗乳腺癌转移的潜力。在本研究中,我们检测了从黑种草种子中提取的百里醌(TQ)对乳腺癌细胞中CXCR4表达和调控的潜在作用。发现TQ以剂量和时间依赖性方式抑制MDA-MB-231三阴性乳腺癌(TNBC)细胞中CXCR4的表达。值得注意的是,TQ对CXCR4的抑制可能是转录调控的,因为用该药物处理会导致活化B细胞核因子κB轻链增强子(NF-κB)激活下调,并抑制NF-κB与CXCR4启动子的结合。用蛋白酶体抑制剂和/或溶酶体稳定剂预处理并不影响TQ诱导的CXCR4抑制。CXCR4的下调进一步与CXCL12介导的MDA-MB-231细胞迁移和侵袭的抑制相关。有趣的是,观察到p65的缺失可逆转TQ在乳腺癌细胞中观察到的抗侵袭/抗迁移作用。在鸡胚绒毛尿囊膜试验模型中,TQ还以剂量依赖性方式抑制MDA-MB-231肿瘤生长和肿瘤血管生成。我们还观察到,在转移性乳腺癌小鼠模型中,TQ(2和4mg/kg)治疗以剂量依赖性方式显著抑制了多个肺、脑和骨转移。有趣的是,对从TQ处理的小鼠分离的骨进行苏木精-伊红(H&E)和免疫组织化学分析表明,溶骨性病变的数量和转移生物标志物的表达减少。总之,结果表明TQ主要通过下调NF-κB调节的CXCR4表达发挥其抗转移作用,因此具有治疗乳腺癌的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a2/6288203/9dc7225ed6a1/fphar-09-01294-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验